ΔNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: Identification of Cox-2 as a novel p63 target

Journal of Pathology

Volumn 218, Issue 4, 2009, Pages 428-436

  Boldrup, Linda ^a   Coates, Philip J ^b   Gu, Xiaolian ^a   Nylander, Karin ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cell lines; Cox 2; Microarray; p63; SCCHN

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROTEIN; PROTEIN P63; PROTEIN P63ALPHA; PROTEIN P63BETA; PROTEIN P63GAMMA; UNCLASSIFIED DRUG; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; EPITHELIUM; GENE CONTROL; GENE EXPRESSION PROFILING; GENE INDUCTION; GENE OVEREXPRESSION; GENE REPRESSION; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING; CHROMATIN IMMUNOPRECIPITATION; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CYCLOOXYGENASE 2; ENZYME INDUCTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 67650862791     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2560     Document Type: Article

References (52)

1. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-713.
2. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-316.
3. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-718.
4. Westfall MD, Pietenpol JA. p63: molecular complexity in development and cancer. Carcinogenesis 2004;25:857-864.
5. Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 2002;22:8659- 8668.
6. Serber Z, Lai HC, Yang A, Ou HD, Sigal MS, Kelly AE, et al. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol 2002;22:8601-8611.
7. King KE, Ponnamperuma RM, Gerdes MJ, Tokino T, Yamashita T, Baker CC, et al. Unique domain functions of p63 isotypes that differentially regulate distinct aspects of epidermal homeostasis. Carcinogenesis 2006;27:53-63.
8. Shirai K, O'Brien PE. Molecular targets in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol 2007;8:239-251.
9. Jefferies S, Foulkes WD. Genetic mechanisms in squamous cell carcinoma of the head and neck. Oral Oncol 2001;37:115-126.
10. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000;97:5462-5467.
11. Foschini MP, Gaiba A, Cocchi R, Pennesi MG, Gatto MR, Frezza GP, et al. Pattern of p63 expression in squamous cell carcinoma of the oral cavity. Virchows Arch 2004;444:332-339.
12. Lo Muzio L, Santarelli A, Caltabiano R, Rubini C, Pieramici T, Trevisiol L, et al. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol 2005;36:187-194.
13. Thurfjell N, Coates PJ, Vojtesek B, Benham-Motlagh P, Eisold M, Nylander K. Endogenous p63 acts as a survival factor for tumour cells of SCCHN origin. Int J Mol Med 2005;16:1065-1070.
14. Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000;60:4016-4020.
15. Deyoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene 2007;26:5169-5183.
16. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 2006;66:7589-7597.
17. Boldrup L, Coates PJ, Gu X, Nylander K. ΔNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J Pathol 2007;213:384-391.
18. Gu X, Coates PJ, Boldrup L, Nylander K. p63 contributes to cell invasion and migration in squamous cell carcinoma of the head and neck. Cancer Lett 2008.
19. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M,Mills AA, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 2006;8:551-561.
20. Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos G, Zhanxiang W, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002;198:417-427.
21. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 2004;114:2063-2072.
22. Thurfjell N, Coates PJ, Uusitalo T, Mahani D, Dabelsteen E, Dahlqvist A, et al. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 2004;25:27-35.
23. Di Iorio E, Barbaro V, Ruzza A, Ponzin D, Pellegrini G, De Luca M. Isoforms of ΔNp63 and the migration of ocular limbal cells in human corneal regeneration. Proc Natl Acad Sci USA 2005;102:9523-9528.
24. Osada M, Park HL, Nagakawa Y, Yamashita K, Fomenkov A, Kim MS, et al. Differential recognition of response elements determines target gene specificity for p53 and p63 . Mol Cell Biol 2005;25:6077- 6089.
25. Benoit V, de Moraes E, Dar NA, Taranchon E, Bours V, Hautefeuille A, et al. Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-κB. Oncogene 2006;25:5708-5718.
26. Gu X, Coates PJ, Maccallum SF, Boldrup L, Sjostrom B, Nylander K. TRAF4 is potently induced by TAp63 isoforms and localised according to differentiation in SCCHN. Cancer Biol Ther 2007;6:1-5.
27. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR, et al. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell 2006;24:593-602.
28. Sharma C, Kaur J, Shishodia S, Aggarwal BB, Ralhan R. Curcumin down-regulates smokeless tobacco-induced NF-κB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology 2006;228:1-15.
29. Konson A, Mahajna JA, Danon A, Rimon G, Agbaria R. The involvement of nuclear factor-κB in cyclooxygenase-2 over-expression in murine colon cancer cells transduced with herpes simplex virus thymidine kinase gene. Cancer Gene Ther 2006;13:1093-1104.
30. Ulivi V, Giannoni P, Gentili C, Cancedda R, Descalzi F. p38/NF-κB-dependent expression of COX-2 during differentiation and inflammatory response of chondrocytes. J Cell Biochem 2008;104:1393-1406.
31. Sawhney M, Rohatgi N, Kaur J, Shishodia S, Sethi G, Gupta SD, et al. Expression of NF-κB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer 2007;120:2545-2556.
32. King KE, Ponnamperuma RM, Allen C, Lu H, Duggal P, Chen Z, et al. The p53 homologue ΔNp63α interacts with the nuclear factor-κB pathway to modulate epithelial cell growth. Cancer Res 2008;68:5122-5131.
33. Candi E, Terrinoni A, Rufini A, Chikh A, Lena AM, Suzuki Y, et al. p63 is upstream of IKKα in epidermal development. J Cell Sci 2006;119:4617-4622.
34. Testoni B, Borrelli S, Tenedini E, Alotto D, Castagnoli C, Piccolo S, et al. Identification of new p63 targets in human keratinocytes. Cell Cycle 2006;5:2805-2811.
35. Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC, et al. ΔNp63α and TAp63α regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 2003;63:2351-2357.
36. Vigano MA, Lamartine J, Testoni B, Merico D, Alotto D, Castagnoli C, et al. New p63 targets in keratinocytes identified by a genome-wide approach. EMBO J 2006;25:5105-5116.
37. Boldrup L, Coates PJ, Hedberg Y, Sjostrom B, Dahlqvist A, Nylander K. Expression of p63, COX-2, EGFR and β-catenin in smokers and patients with squamous cell carcinoma of the head and neck reveal variations in non-neoplastic tissue and no obvious changes in smokers. Int J Oncol 2005;27:1661-1667.
38. Chen WC, McBride WH, Chen SM, Lee KF, Hwang TZ, Jung SM, et al. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies. Head Neck 2005;27:503-512.
39. Nix P, Lind M, Greenman J, Stafford N, Cawkwell L. Expression of Cox-2 protein in radioresistant laryngeal cancer. Ann Oncol 2004;15:797-801.
40. Terakado N, Shintani S, Yano J, Chunnan L, Mihara M, Nakashiro K, et al. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol 2004;40:383-389.
41. Han JA, Kim JI, Ongusaha PP, Hwang DH, Ballou LR, Mahale A, et al. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J 2002;21:5635-5644.
42. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999;274:10911-10915.
43. Nishi H, Senoo M, Nishi KH, Murphy B, Rikiyama T, Matsumura Y, et al. p53 homologue p63 represses epidermal growth factor receptor expression. J Biol Chem 2001;276:41717-41724.
44. Wu G, Osada M, Guo Z, Fomenkov A, Begum S, Zhao M, et al. ΔNp63α up-regulates the Hsp70 gene in human cancer. Cancer Res 2005;65:758-766.
45. Romano RA, Birkaya B, Sinha S. A functional enhancer of keratin14 is a direct transcriptional target of ΔNp63. J Invest Dermatol 2007;127:1175-1186.
46. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006;38:1654-1661.
47. Chikh A, Sayan E, Thibaut S, Lena AM, DiGiorgi S, Bernard BA, et al. Expression of GATA-3 in epidermis and hair follicle: relationship to p63. Biochem Biophys Res Commun 2007;361:1-6.
48. Marinari B, Ballaro C, Koster MI, Giustizieri ML, Moretti F, Crosti F, et al. IKKα is a p63 transcriptional target involved in the pathogenesis of ectodermal dysplasias. J Invest Dermatol 2008.
49. Fomenkov A, Huang YP, Topaloglu O, Brechman A, Osada M, Fomenkova T, et al. P63α mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome. J Biol Chem 2003;278:23906-23914.
50. Huang YP, Kim Y, Li Z, Fomenkov T, Fomenkov A, Ratovitski EA. AEC-associated p63 mutations lead to alternative splicing/ protein stabilization of p63 and modulation of Notch signaling. Cell Cycle 2005;4:1440-1447.
51. Thornton JK, Dalgleish C, Venables JP, Sergeant KA, Ehrmann IE, Lu X, et al. The tumour-suppressor protein ASPP1 is nuclear in human germ cells and can modulate ratios of CD44 exon V5 spliced isoforms in vivo. Oncogene 2006;25:3104-3112.
52. de Moraes E, Dar NA, de Moura Gallo CV, Hainaut P. Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: balancing life and death during inflammatory stress and carcinogenesis. Int J Cancer 2007;121:929-937.